Aethlon Medical (AEMD) Maxim Group’s 2024 Healthcare Virtual Summit summary

Conference overview

• Virtual Healthcare Conference hosted over 85 public companies, with CEO-led webinars and three panel discussions across three days, concluding October 17th.

• Presentations included updates and Q&A sessions, focusing on company strategies and clinical progress.

Product and clinical focus

• The Hemopurifier is a single-use device for blood filtration, targeting viral particles and extracellular vesicles (EVs) in patients, especially those with solid tumors failing anti-PD-1 therapy.

• Clinical trials are underway in three hospitals in Australia and one in India, with ethics board approvals and staff training in progress.

• Recruitment for oncology trials is beginning, targeting patients who do not respond to Keytruda or Opdivo, representing a large potential market.

• The device aims to remove EVs that may block immune checkpoint inhibitors, potentially improving patient response rates.

• Oncology is the primary focus due to market size and recurring need, with a reduced burn rate to extend operational runway.

Clinical trial design and timeline

• Trials in Australia and India will enroll 9–18 patients each, starting with a safety cohort of three patients receiving weekly treatments.

• Blood samples will be analyzed for EV reduction and T-cell marker improvements, with safety as the main endpoint.

• The first patient treatments are expected this quarter, with initial data anticipated a quarter later.

• If safety is confirmed, a larger pivotal trial will follow, likely involving fewer than 100 patients.

• Key opinion leaders in Australia and India are leading the trials, with potential for future U.S. involvement.